Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Multiple studies had already shown that their benefits might go beyond weight loss and diabetes. Those studies showed that patients taking GLP-1 medication fared better against a wide range of health ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...